1076 Enhanced the therapeutic effects of desoximetasone by inhibiting cytochrome P450 3A4 metabolism in the imiquimod-induced psoriasis animal model

Psoriasis is a common chronic, recurrent, immune-mediated disease of the skin and joints. In psoriasis, epidermal hyperproliferation, abnormal keratinocyte differentiation, angiogenesis with blood vessel dilatation excess Th-1 Th-17 infiltration can be observed. A broad spectrum anti-psoriatic treatments, both topical systemic, are available for management psoriasis. However, there still no curative treatment all treatments may induce adverse effects without appropriate supervision. Therefore, finding safe, effective, long-lasting product to enhance psoriasis' therapeutic effect important. Human keratinocytes murine express various cytochromes P450 enzymes, including 3A4. Cytochromes 3A4 participate in about 30% biotransformation/metabolism drugs. Desoximetasone known as corticosteroids substrate used relieve conditions such dermatoses, allergies, Our previous study demonstrated that 3A excipient inhibitor-based microemulsion formulation could promising concept drugs Microemulsion also work an emollient provide sufficiently hydration low-grade inflammatory condition. results show 0.05% desoximetasone loaded enzyme inhibitor base restores imiquimod induced barrier disruption showed fewer severe clinical pathological features than commercial 0.25% ointment 0.5% clobetasol ointment. The might new drug development diseases treatment.